Fenofibrate 145mg 20 tablets
Severe hypertriglyceridemia with or without low HDL cholesterol; mixed hyperlipidemia in cases where the use of statins is contraindicated or there is intolerance to statins; mixed hyperlipidemia in patients at high cardiovascular risk, in addition to statin therapy, when triglycerides and high-density lipoprotein cholesterol levels are not adequately controlled.
active ingredient: fenofibrate; 1 tablet contains 145 mg fenofibrate;
excipients: hypromellose, docusate sodium, sucrose, sodium lauryl sulfate, lactose, silicified microcrystalline cellulose, crospovidone, magnesium stearate, Opadry® OY-B-28920 (polyvinyl alcohol, titanium dioxide (E 171), talc, soy lecithin, xanthan gum) .
– Severe hypertriglyceridemia, including those with low HDL cholesterol;
– Mixed hyperlipidemia where use of statins is contraindicated or intolerant of statins;
– Mixed hyperlipidemia in patients at high cardiovascular risk in addition to statin therapy when triglycerides and HDL cholesterol are not adequately controlled.
– Diabetic retinopathy: Tricor 145 mg is indicated for reducing the progression of diabetic retinopathy in patients with type 2 diabetes and diabetic retinopathy existing.
Hepatic insufficiency (including biliary cirrhosis and UNDECIDED persistent liver dysfunction).
Established gallbladder disease.
Severe chronic kidney disease.
Chronic or acute pancreatitis, except in cases of acute pancreatitis caused severe hypertriglyceridemia.
Installed photodermatitis or phototoxic reaction during treatment fibrates or ketoprofen.
Hypersensitivity to the active substance or to any excipient.
Also Tricor 145 mg should not be used in patients allergic to peanuts, peanut oil or soya lecithin or similar products because of the risk of hypersensitivity reactions.
Dosage & Administration
Tablets, film-coated shell, can be taken at any time during the day regardless of the meal. Tablets should be swallowed whole with a glass of water.
Diet begun to the use of the drug, must continue.
During the treatment of hyperlipidemia treatment efficacy should be monitored by determining the levels of lipids in the blood serum. If after several months (eg 3 months) is not achieved an adequate response to treatment should be considered additional or different therapeutic measures.
The recommended dose is one tablet containing 145 mg fenofibrate, 1 time a day. Patients who take 1 capsule containing 200 mg of fenofibrate, or 1 tablet containing 160 mg fenofibrate, you can replace them with one pill Tricor 145 mg without further dose selection.
If the patient should be used with fenofibrate two indications (hyperlipidemia and diabetic retinopathy) should take only one tablet Tricor 145 mg per day.
Elderly patients that have renal insufficiency, the usual dose recommended for adults.